injectable glp 1 agonists GLP-1 Medications: Everything You Need to Know List of approved and pending
Description
Pemvidutide is also undergoing phase 2 studies as MASH treatment
These differences may also explain differences in gastrointestinal adverse reactions, such as nausea and vomiting, which are common with GLP-1RAs but typically diminish over time [127, 128]
57,684 patients: nausea RR 2.90, vomiting RR 3.60, diarrhea RR 1.97
doi: 10.1055/s-0042-101794
